Citations

Clear

7 citation(s) found for "Lee, Soyon".

Time‐Related Burden of Treatment With Parenterally Administered Complement Inhibitors: A Mixed Methods Observational Study Exploring Experiences among Patients With Paroxysmal Nocturnal Hemoglobinuria
Dingli, David , Broderick, Lynne , Rizio, Avery A. , Rucker, Sloan, LaGasse, Kaitlin , White, Michelle K. , Burton, Elise, Gordon, S., Yen, Glorian P., Paulose, Jincy, Geevarghese, Anumaxine, Lee, Soyon , Carty, Michelle K , Dingli, David , Gordon, Shaquilla, Geevarghese, Anumaxine Lincy

Mayo Clinic

Health Science Reports | June 20, 2026 | Volume: 9 | Issue: 6 | Pages: No page available

10.1002/hsr2.72585 | PMID 42327465 Get It

Real-world treatment patterns and clinical outcomes among patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan in the United States
Dingli, David, Lee, Soyon, Kuypers, Nicholas, Paulose, Jincy, Bilano, Ver, Nusser, Hayley, Buchan, Tayler, Buchan, Claire, Jaffe, Rachel, Waheed, Anem, Dingli, David, Lee, Soyon, Kuypers, Nicholas, Paulose, Jincy, Bilano, Ver, Nusser, Hayley, Buchan, Tayler, Buchan, Claire, Jaffe, Rachel, Waheed, Anem

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1429-1429

10.1182/blood-2025-1429 Get It

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening hematological disorder affecting ≈24 per 1,000,000 people in the US. Iptacopan, the first orally administered monotherapy for PNH, received US Food and Drug Administration approval in December 2023. APPRISE-PNH is a data platform designed to capture comprehensive real-world information on iptacopan-treated patients with PNH. The aim of this study was to describe patient profiles and assess treatment patterns and clinical outcomes among iptacopan-treated patients (age ≥18 years) with PNH in the US real-world setting. Methods: The present interim analysis of APPRISE-PNH includes data from patients enrolled between July 2, 2024, and June 13, 2025, with additional data collection expected through 2025. Duration of therapy was measured from the date of iptacopan initiation (index) until discontinuation or data cutoff, whichever occurred first. Treatment adherence was measured using the medication possession ratio (MPR; ratio of the total days' supply to days covered) and the proportion of days covered (PDC; ratio of days with supply to days covered). Clinical outcomes were assessed during follow-up including hemoglobin (Hb; change from pre-index to highest level post index, proportion of patients with Hb increase ≥2 g/dL, and proportion of patients with Hb normalization to ≥12 g/dL), lactate dehydrogenase (LDH) (change from pre-index to lowest level post index and proportion of patients with LDH reduction <1.5× upper limit of normal [ULN]), and number of red blood cell (RBC) transfusions. Results: Among 52 patients enrolled as of June 13, 2025, the median age was 53.7 years, 38% were male, and 60% were covered by commercial insurance. Overall, 25% of patients (n=13) were complement inhibitor (CI) naive at the time of iptacopan initiation, while 75% (n=39) were treatment experienced and had received ≥1 prior CI therapy for PNH (77% ravulizumab, 46% eculizumab, 26% pegcetacoplan). All patients received iptacopan 200 mg twice daily, per the product label; the median (IQR) duration of iptacopan therapy was 9.8 (5.0-12.8) months. At the time of data cutoff, 2 patients discontinued therapy (1 due to provider decision, 1 due to death). The median (IQR) MPR and PDC were 105.2% (100.6%-110.7%) and 97.3% (92.7%-99.5%), respectively. Among the 52 patients enrolled in APPRISE-PNH, 42 patients had medical records available at the time of data cutoff. Of the 23 of 42 patients (55%) with Hb values available pre- and post index at the time of data cutoff, 4 were CI treatment naive (median [IQR] pre-index Hb, 9.9 [9.1-10.2] g/dL) and 19 were CI treatment experienced (median [IQR] pre-index Hg, 10.7 [8.9-12.2] g/dL). The median (IQR) change from pre-index to highest value post-index was similar for both groups (1.6 [0.8-2.3] g/dL and 1.6 [0.6-3.4] g/dL, respectively). However, among the CI treatment–experienced patients, those with pre-index Hb <12 g/dL (n=11) experienced a greater improvement than those with pre-index Hb ≥12 g/dL (n=8), with median (IQR) of 3.3 (2.2-4.5) g/dL vs 0.4 (0.1-1.3) g/dL, respectively. Overall, 12 of 23 patients (52%) achieved a Hb increase ≥2 g/dL, and 17 of 23 (74%) achieved Hb normalization to ≥12 g/dL. Among the 18 of 42 patients (43%) with LDH values available pre- and post index, the median (IQR) change from pre-index to lowest post-index value was −41.5 (−155.8 to 2.5) U/L. Among those with clinical data, most patients (38 of 42; 90%) did not require RBC transfusions during follow-up and 4 had evidence of an RBC transfusion over the follow-up period; 2 of 4 patients requiring transfusions had aplastic anemia and/or myelodysplastic syndrome. At the time of data cutoff, no patients with clinical data available had evidence of a major adverse vascular event (including thrombosis, transient ischemic attack, stroke, and major bleeding) over the follow-up period. Conclusions: These data represent early insights into the real-world use of iptacopan and related Hb response in US patients with PNH. Adherence to iptacopan was high, and iptacopan treatment improved Hb and LDH parameters, providing comprehensive hemolysis control. Enrollment is currently ongoing; data on additional patients with longer follow-up are forthcoming.
Management of a real-world cohort of patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: A multi-institutional analysis
Orland, Mark, Thiagarajan, Praveena, Unlu, Serhan, Ahmed, Arooj, Bravo-Perez, Carlos, Addona, Matteo D, Basch, Megan, Lee, Soyon, Bilano, Ver, Paulose, Jincy, Geevarghese, Lincy, Bollu, Vamsi, Dingli, David, Maciejewski, Jaroslaw, Gurnari, Carmelo, Orland, Mark, Thiagarajan, Praveena, Unlu, Serhan, Ahmed, Arooj, Bravo-Perez, Carlos, Addona, Matteo D, Basch, Megan, Lee, Soyon, Bilano, Ver, Paulose, Jincy, Geevarghese, Lincy, Bollu, Vamsi, Dingli, David, Maciejewski, Jaroslaw, Gurnari, Carmelo

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1430-1430

10.1182/blood-2025-1430 Get It

Abstract Introduction: Iptacopan, the first oral complement inhibitor, offers an attractive alternative to parenteral complement blockers in paroxysmal nocturnal hemoglobinuria (PNH). While clinical trials have confirmed its efficacy vs terminal C5 inhibition, real-world data on breakthrough hemolysis (BTH), complement-activating conditions (CACs), and switching patients with satisfactory response to prior therapy (hemoglobin [Hgb] ≥10 g/dL) are limited. We studied a large multi-institutional PNH cohort treated with iptacopan. Methods: We performed a retrospective analysis of 62 patients with PNH who received iptacopan for ≥3 months between FDA approval in December 2023 and April 2025 (mean exposure, 1.01 years; 62 patient-years). Patients from the Cleveland Clinic network and Mayo Clinic were analyzed. Demographics, prior therapies, reasons for transition, Hgb, lactate dehydrogenase (LDH), platelet counts, thrombotic events, CACs, BTH, and adverse events were extracted. Efficacy was assessed separately for treatment-naive patients and treatment-experienced patients (sub-optimal responders [Hgb <10 g/dL] and optimal responders to prior therapy). Results: Overall, 12 of 62 patients were treatment naive and 50 switched from prior therapy (of whom 21 had sub-optimal responses and 29 had optimal responses). In the 50 patients who switched, 60% transitioned from ravulizumab, 30% from pegcetacoplan, 8% from eculizumab, and 2% from ravulizumab and danicopan. The primary reasons for switching were the convenience of oral medications (n=17), extravascular hemolysis or BTH (n=10), prior medication side effects (n=5), desire to further improve Hgb (n=6), and not documented (n=12). A total of 4 patients discontinued iptacopan (2 pregnancies, 1 insurance reversal, 1 intolerable gastrointestinal toxicity). Three patients reported headaches, and 1 reported abdominal pain; all resolved within 1 week from treatment start. Across the 62 patient-years, no thrombotic events occurred, 18 CAC episodes were managed with iptacopan 200 mg BID (10 infections, 1 heart-failure exacerbation, 2 minor surgeries, 1 traumatic brain injury, 2 pancreatitis, 2 pregnancies), and none triggered BTH. Overall, 3 clinically significant BTH events (in 3 patients; 4.8% annualized) were recorded: 2 infection-related (managed outpatient) and 1 alcoholic pancreatitis; all resolved with a 1- to 2-day increase to iptacopan 400 mg BID ± single-dose eculizumab. Two hemolytic events secondary to non-adherence were reported (4 days after stopping iptacopan). These resolved after resuming iptacopan 200 mg BID without need for hospitalization. In treatment-naive patients, mean Hgb increased significantly by 1.87 g/dL from iptacopan initiation (baseline) to 3 months (9.9±1.9 to 11.8±1.3 g/dL; P=.005), sustained until last follow-up at 12 months. LDH decreased by 369 U/L at 3 months (P=.058), sustained through 12 months. No significant change was seen in platelets, absolute neutrophil count (ANC), or white blood cell (WBC) count. In treatment-experienced sub-optimal responders, mean Hgb increased significantly by 2.16 g/dL from baseline to 3 months (8.6±.89 to 10.8±2.1; P<0.001). At 12 months, 85% of patients had increased Hgb compared with baseline (median increase: 3.31±1.62 g/dL). LDH decreased significantly from baseline to 3 months by 229 U/L (P=.03), with no significant changes noted in LDH from 3 to 12 months or in platelets, ANC, or WBC counts. In previously treated complement inhibitor responders, mean Hgb increased significantly by 0.75 g/dL from baseline to 3 months (12.0±1.3 to 12.8±1.7 g/dL; P=.004), with 79% showing improvements from baseline at 12-month follow-up (median increase: 1.16±0.82 g/dL). LDH decreased significantly by 45 U/L from baseline to 3 months (P=.03), with no further significant changes from 3 to 12 months. Conclusions: In this real-world cohort, iptacopan provided substantial and durable hemoglobin improvement across naive and previously treated patients with PNH, with meaningful reduction in hemolytic parameters, absence of thrombosis, and low BTH rate predominantly linked to infection. Patients with previous satisfactory responses also showed improved Hgb levels. The favorable safety profile and high treatment persistence underscore iptacopan's role as an effective first-line or switch therapy and support its incorporation into evidence-based sequencing algorithms in the evolving PNH treatment landscape.
Navigating the complement cascade: A multicenter journey from pegcetacoplan to iptacopan in paroxysmal nocturnal hemoglobinuria
Thiagarajan, Praveena, Orland, Mark, Unlu, Serhan, Ahmed, Arooj, Bravo-Perez, Carlos, Addona, Matteo D, Basch, Megan, Lee, Soyon, Bilano, Ver, Paulose, Jincy, Geevarghese, Lincy, Bollu, Vamsi, Sanikommu, Srinivasa Reddy, Dingli, David, Maciejewski, Jaroslaw, Gurnari, Carmelo, Thiagarajan, Praveena, Orland, Mark, Unlu, Serhan, Ahmed, Arooj, Bravo-Perez, Carlos, Addona, Matteo D, Basch, Megan, Lee, Soyon, Bilano, Ver, Paulose, Jincy, Geevarghese, Lincy, Bollu, Vamsi, Sanikommu, Srinivasa Reddy, Dingli, David, Maciejewski, Jaroslaw, Gurnari, Carmelo

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1433-1433

10.1182/blood-2025-1433 Get It

Abstract Introduction: The therapeutic landscape for paroxysmal nocturnal hemoglobinuria (PNH) has rapidly evolved with multiple proximal complement inhibitors now available, including pegcetacoplan (C3 inhibitor) and iptacopan (oral factor B inhibitor). While clinical trials have established individual drug efficacy compared with terminal complement inhibitors, real-world evidence regarding therapeutic transitions between proximal complement inhibitors remains extremely limited. As patients and clinicians increasingly seek to optimize treatment through sequential therapy approaches, understanding the outcomes of transitioning from pegcetacoplan to iptacopan becomes critical for evidence-based treatment sequencing in this rare hematologic disorder. Methods: We conducted a retrospective multicenter analysis across 3 academic medical centers (Cleveland Clinic, Mayo Clinic, Levine Cancer Institute) that evaluated 15 consecutive patients with PNH who were considered for transition from pegcetacoplan to iptacopan. Patients had confirmed PNH by flow cytometry and ≥3 months pegcetacoplan exposure. After switching to iptacopan, we assessed treatment acceptance rates, demographic characteristics, clinical outcomes including hemoglobin and lactate dehydrogenase (LDH) levels, and safety parameters. Responses to iptacopan were classified as optimal (hemoglobin >10.5 g/dL with clinical improvement) or suboptimal. Statistical analysis used paired t tests for continuous variables. Results: Of the 15 patients evaluated (median age [range]: 53 [22-81] years; 73% female), 14 patients (93.3%) elected to transition to iptacopan, demonstrating high treatment acceptance. Disease subtypes included classic PNH (36%) and PNH (64%) in the setting of another bone marrow disorder (n=7), multiple myeloma (n=1), and myelofibrosis (n=1). Median (range) duration of pegcetacoplan treatment pre-switch was 3 months (2-7 months), and median (range) duration of iptacopan treatment was 24 months (6-36 months). Among patients who transitioned, 79% (11/14) achieved hemoglobin improvement, with a mean increase from 9.2±1.8 to 10.8±2.1 g/dL (P=.028). Overall, optimal response was achieved in 64% (9/14) of patients. Response rates varied significantly by disease subtype: 80% in patients with classic PNH vs 56% in patients with PNH and aplastic anemia, with particularly poor outcomes in patients with concurrent hematologic malignancies (0%). LDH levels improved in 86% of patients, decreasing from 400±152 to 310±95 U/L (P=.015). PNH clone sizes remained stable throughout transition (erythrocyte: 75.1%±9.2% vs 75.4%±9.4%, P=.62; granulocyte: 95.0%±3.9% versus 95.2%±4.0%, P=.45). Treatment was well tolerated with no serious adverse events, breakthrough hemolysis, thrombosis, or discontinuations required. Two patients experienced mild self-limited gastrointestinal symptoms. Conclusions: This first multicenter real-world analysis demonstrates that the pegcetacoplan-to-iptacopan transition provides clinical benefit in the majority of this initial set of patients with PNH, with significant improvements in hemoglobin and an excellent safety profile while maintaining clone stability. The high acceptance rate suggests that patients prefer oral therapy over subcutaneous administration. These findings address a critical knowledge gap in proximal complement inhibitor sequencing, suggesting that iptacopan is an effective therapeutic option for patients with inadequate pegcetacoplan response and supporting the development of evidence-based treatment algorithms for optimal PNH care in the era of multiple complement inhibitor options.
Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden
Zhang, Connie, McStocker, Samantha, Healey, Amanda, Kuypers, Nicholas, Chanpura, Mohin , Anwar, Hiba , Paulose, Jincy, Lee, Soyon , Seth, Puja , Yen, Glorian , Dingli, David , Healey, Amanda, Kuypers, Nicholas, Seth, Puja

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2327-2327

10.1182/blood-2024-211194 Get It

Background and significance: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition caused by a somatic mutation in the PIG-A gene, leading to complement-mediated hemolysis and severe complications such as anemia and thrombosis. Patients often experience fatigue, dyspnea, and abdominal pain, impacting their daily lives and emotional well-being. This study aims to comprehensively explore the impact of PNH on health-related quality of life (HRQoL), alongside real-world treatment utilization and symptom burden patterns, especially as new treatments become available to this patient population. These results are based on interim baseline data from currently enrolled study participants, providing an initial assessment of their PNH disease experience. This analysis does not include any data collected prospectively during the data collection period. Study design and methods: This ongoing, prospective, observational study (NCT06411626) aims to enroll at least 128 US-based participants aged 18 or older with PNH, regardless of treatment usage. Participants are recruited through clinician-based referrals, patient advocacy organizations, and community-based online channels. All activities can be completed remotely using the Folia Health app, the single site for this study. This app-based study aims to comprehensively assess patient-reported symptom burden, treatment use patterns, and impacts of PNH on health and FACIT-Fatigue through self-reported home-reported outcomes (HROs). Participants will track symptoms and treatment use, including recently approved treatments (e.g., iptacopan, danicopan, crovalimab). HROs consist of participants' self-identified symptoms and personalized treatment plan that are tracked longitudinally against self-reported baselines. Semi-structured interviews and collaborative feedback sessions with PNH patients and clinicians yielded a comprehensive outcomes inventory for tracking key health outcomes specific to PNH. This inventory includes the ability to track infusion treatments and denote flare-ups in fatigue. Participants can customize their data collection to track symptoms in additional domains beyond those initially suggested (e.g., respiratory or immune). At enrollment, participants report baseline health status and select their relevant symptoms and treatments to routinely track for 6 months. Monthly in-app surveys will collect data on overall health and the FACIT- Fatigue. The Folia app allows participants to visualize symptoms trends, set treatment reminders, and generate reports for their care team. Results: Enrollment began on June 11, 2024. As of July 22, 2024, an interim data analysis was conducted on 20 participants; 65% (n=13) enrolled through online community-based channels and 35% (n=7) enrolled through clinic referrals. Participants selected 37 distinct symptoms and measurements and 26 distinct treatments to track over the 6-month period. The most common symptoms selected at baseline include fatigue (n=19), brain fog (n=17), and dark colored urine (n=15). PNH treatments selected for tracking include iptacopan (n=9), ravulizumab (n=5), eculizumab (n=4), and pegcetacoplan (n=3). The mean baseline FACIT- Fatigue score (n=18) was 35.7 and the median was 40 (IQR= 16). Further descriptive analyses stratified by primary treatment use will be conducted assessing characteristics of symptom burden, satisfaction with treatments-in-use, and self-reported impact on HRQoL. Conclusions: Initial interim baseline data of recently enrolled participants with PNH show a variable disease experience. This app-based, observational study aims to establish a new real-world data source to understand patient priorities related to symptom variability, treatment patterns and preference, and impacts of condition management on HRQoL.
Early Insights into Real-World Iptacopan Use Among Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States: The Apprise-PNH Data Platform
Yen, Glorian , Kuypers, Nicholas, Paulose, Jincy, Chanpura, Mohin , Lee, Soyon , Barone, Joseph G., Stutts, Jacob, Buchan, Tayler A. , Buchan, Claire, Kim, Inkyu , Waheed, Anem , Dingli, David , Stutts, Jacob, Tang, Jackson

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 5668-5668

10.1182/blood-2024-194425 Get It

Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening hematological disorder affecting approximately 24 people per million in the United States (US). Iptacopan, the first orally administered monotherapy for PNH, received US Food and Drug Administration approval in December 2023. APPRISE-PNH (A Patient Platform for Real-world data on Iptacopan in the United StatEs for patients with PNH) is a data platform designed to capture comprehensive real-world information on patients with PNH treated with iptacopan in the US. This interim analysis aims to provide early insights into the characteristics and treatment patterns of patients enrolled in APPRISE-PNH to date. Methods: APPRISE-PNH is a retrospective, longitudinal, data platform including adult patients (age ≥18 years) with PNH treated with iptacopan in the US real-world setting. Consenting patients in the US are recruited through the iptacopan distribution network. The present analysis includes data from patients enrolled between July 2 and July 26, 2024, with additional data collection expected through the remainder of 2024 and 2025. Patient characteristics and treatment patterns were evaluated descriptively. Duration of therapy was measured from the date of iptacopan initiation until the date of iptacopan discontinuation or data cut-off, whichever occurred first. Treatment adherence was measured using both the medication possession ratio (MPR), calculated as the ratio of the total days supply to days covered, and the proportion of days covered (PDC), calculated as the ratio of days with supply to days covered. Results: As of July 26th, 2024, nine patients with PNH have enrolled in the APPRISE-PNH data platform. The median age at the start of iptacopan therapy was 44 years (interquartile range [IQR] 40-73 years), seven (78%) patients were female, and four (44%) were covered by commercial insurance. Overall, two (22%) patients were treatment-naïve at the start of iptacopan therapy, while seven (78%) patients had received prior complement-inhibitor (CI) therapy for PNH (44% ravulizumab, 44% eculizumab, 33% pegcetacoplan). The median duration of iptacopan therapy was 2.0 months (IQR 1.5-2.9 months). All patients received iptacopan 200 mg twice daily (as per the product label) and the median number of fills was 2.0 (IQR 1.0-3.0). At the time of data cut-off, no patients had discontinued iptacopan therapy. The MPR in this group of patients was 136% (IQR 114%-150%) and PDC was 100% (IQR 100%-100%). Conclusions: These are the first data from the APPRISE-PNH data platform and represent the first insights into real-world use of iptacopan in the US. Many patients enrolled in APPRISE-PNH had previously received CI therapy for PNH. Treatment adherence, as indicated by both the MPR and PDC, was high across iptacopan-treated patients. Enrollment into the APPRISE-PNH data platform is currently ongoing; data from additional patients, additional laboratory and clinical outcomes, and longer follow-up data are expected to be available at the time of presentation.
Health-Related Quality of Life and Symptom-Specific Functional Impairment Among Patients Treated with Parenterally Administered Complement Inhibitors for Paroxysmal Nocturnal Hemoglobinuria
LaGasse, Kaitlin , Carty, Michelle, Burton, Elise, Gordon, S., Weigand, Leslie C., Yen, Glorian , Paulose, Jincy, Geevarghese, Lincy, Lee, Soyon , Dingli, David , Rizio, Avery A. , Broderick, Lynne , Gordon, Shaquilla

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 5126-5126

10.1182/blood-2023-182336 Get It

Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening, stem cell disorder that renders red blood cells vulnerable to complement-mediated hemolysis. This study describes the health-related quality of life (HRQoL) and symptom-specific functional impairment of patients with PNH in a real-world setting. Methods: US-based adults with PNH treated with a parenterally administered complement inhibitor (PACI) for ≥6 months completed an online, cross-sectional, observational survey; a subset of patients also participated in individual semi-structured qualitative interviews after completing the survey. The survey included the PROMIS® 29+2 Profile v2.1 (PROMIS 29+2) to measure HRQoL. The FACIT Fatigue, Neuro-QOL Item Bank v2.0 Cognitive Function Short Form, and PROMIS Item Bank v1.0 Dyspnea Functional Limitations 10a Short Form measured functional impairment associated with specific symptoms of PNH. For each patient with PNH who completed the online survey, up to 3 age- (+/- 3 years) and sex-matched adults without PNH also completed the survey. The HRQoL and functional impairment of the PNH sample was compared to that of general population (GP) sample using independent samples t-tests or Mann-Whitney tests. To further explore the experiences of patients with PNH, the association between HRQoL/functional impairment and fatigue severity was investigated. Patients with PNH were grouped according to their self-reported fatigue severity over the past 7 days (very mild or mild vs moderate, severe, or very severe [no patients reported no fatigue]). Differences in scores across these 2 groups were tested. Data from the qualitative interviews were coded using thematic analysis to explore key concepts related to HRQoL and impairment due to PNH symptoms. Data collection began in March 2023; results are based on interim data. Results: Demographic characteristics of the study samples (PNH survey sample: N=31, GP survey sample: N=62, PNH interview sample: N=10) are shown in Table 1. Patients were treated for PNH with eculizumab, pegcetacoplan, or ravulizumab, with an average duration of current PACI treatment of 3.4 years. Compared to the age and sex-matched GP sample, patients with PNH had significantly higher median scores on the PROMIS 29+2 fatigue domain (GP: 48.70 vs PNH: 57.10, p=0.041) and PROMIS Dyspnea Functional Limitations short form (GP: 40.70 vs PNH: 48.60, p=0.036), indicating that patients with PNH experience more fatigue and dyspnea limitations than the GP sample. Patients with PNH also had significantly lower median scores on the PROMIS 29+2 ability to participate in social roles/activities domain (GP: 53.50 vs PNH: 44.20, p=0.013), indicating greater role/activity limitations among patients with PNH. Compared to the GP sample, patients with PNH had numerically lower (i.e., worse) median PROMIS 29+2 cognitive functioning domain scores (GP: 50.00 vs PNH: 46.30, p=0.058) and FACIT Fatigue scores (GP: 39.50 vs PNH: 30.00, p=0.057). Within the PNH sample, statistically significant associations (p<0.05) were observed between fatigue severity and HRQoL/functional impairment for all outcomes except for the PROMIS 29+2 sleep disturbance and cognitive functioning domains (Table 2). Patients with more severe fatigue had worse HRQoL and more functional impairment than patients with less severe fatigue. Interview participants described fatigue-related functional impairments in their physical, social, and cognitive functioning. Fatigue made daily activities (e.g., cooking, cleaning, going for a walk) difficult and sometimes impossible. Planning social activities in advance was also challenging as patients could not predict how they would feel on any given day, and often found they had to miss, postpone, or cancel social engagements. Finally, patients described experiencing “brain fog” including difficulty concentrating, forgetfulness, and delayed cognitive processing. Conclusions: Despite receiving treatment for PNH, patients experienced deficits in areas of HRQoL related to fatigue, participation in social roles, cognitive function, and functional limitations due to dyspnea, relative to a sample of GP adults. During follow-up interviews, patients emphasized the deep and broad impacts that fatigue and cognitive functioning had, making daily activities and their social lives very difficult.